Related Research Articles
Psychosis is a condition of the mind that results in difficulties determining what is real and what is not real. Symptoms may include delusions and hallucinations, among other features. Additional symptoms are incoherent speech and behavior that is inappropriate for a given situation. There may also be sleep problems, social withdrawal, lack of motivation, and difficulties carrying out daily activities. Psychosis can have serious adverse outcomes.
Schizophrenia is a mental disorder characterized by continuous or relapsing episodes of psychosis. Major symptoms include hallucinations, delusions and disorganized thinking. Other symptoms include social withdrawal and flat affect. Symptoms typically develop gradually, begin during young adulthood, and in many cases are resolved. There is no objective diagnostic test; diagnosis is based on observed behavior, a psychiatric history that includes the person's reported experiences, and reports of others familiar with the person. For a diagnosis of schizophrenia, the described symptoms need to have been present for at least six months or one month. Many people with schizophrenia have other mental disorders, especially substance use disorders, depressive disorders, anxiety disorders and obsessive–compulsive disorder.
Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, behavior, judgment and evaluation, and memory. It is distinguished from neuropsychopharmacology, which emphasizes the correlation between drug-induced changes in the functioning of cells in the nervous system and changes in consciousness and behavior.
Substance abuse, also known as drug abuse, is the use of a drug in amounts or by methods that are harmful to the individual or others. It is a form of substance-related disorder. Differing definitions of drug abuse are used in public health, medical, and criminal justice contexts. In some cases, criminal or anti-social behavior occurs when the person is under the influence of a drug, and long-term personality changes in individuals may also occur. In addition to possible physical, social, and psychological harm, the use of some drugs may also lead to criminal penalties, although these vary widely depending on the local jurisdiction.
Schizoaffective disorder is a mental disorder characterized by abnormal thought processes and an unstable mood. This diagnosis requires symptoms of both schizophrenia and a mood disorder: either bipolar disorder or depression. The main criterion is the presence of psychotic symptoms for at least two weeks without any mood symptoms. Schizoaffective disorder can often be misdiagnosed when the correct diagnosis may be psychotic depression, bipolar I disorder, schizophreniform disorder, or schizophrenia. This is a problem as treatment and prognosis differ greatly for most of these diagnoses.
Cannabis, also known as marijuana among other names, is a psychoactive drug from the cannabis plant. Native to Central or South Asia, the cannabis plant has been used as a drug for both recreational and entheogenic purposes and in various traditional medicines for centuries. Tetrahydrocannabinol (THC) is the main psychoactive component of cannabis, which is one of the 483 known compounds in the plant, including at least 65 other cannabinoids, such as cannabidiol (CBD). Cannabis can be used by smoking, vaporizing, within food, or as an extract.
Amanda Claire Marian Charteris, Countess of Wemyss and March, also known as Amanda Feilding, is an English drug policy reformer, lobbyist, and research coordinator. In 1998, she founded the Foundation to Further Consciousness, later renamed to the Beckley Foundation, a charitable trust which initiates, directs, and supports neuroscientific and clinical research into the effects of psychoactive substances on the brain and cognition. She has also co-authored over 50 papers published in peer-reviewed journals, according to the Foundation. The central aim of her research is to investigate new avenues of treatment for such mental illnesses as depression, anxiety, and addiction, as well as to explore methods of enhancing well-being and creativity.
Dual diagnosis is the condition of having a mental illness and a comorbid substance use disorder. There is considerable debate surrounding the appropriateness of using a single category for a heterogeneous group of individuals with complex needs and a varied range of problems. The concept can be used broadly, for example depression and alcohol use disorder, or it can be restricted to specify severe mental illness and substance use disorder, or a person who has a milder mental illness and a drug dependency, such as panic disorder or generalized anxiety disorder and is dependent on opioids. Diagnosing a primary psychiatric illness in people who use substances is challenging as substance use disorder itself often induces psychiatric symptoms, thus making it necessary to differentiate between substance induced and pre-existing mental illness.
Bankole A. Johnson, DSc, MD, MPhil, FRCPsych is a licensed physician and board-certified psychiatrist throughout Europe and the United States who served as Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia. Johnson's primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, is an effective treatment for alcoholism. Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, "Addiction", which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. Professor Johnson recently accepted an appointment to join the University of Maryland as the Chairman of Psychiatry and to lead a Brain Science Research Consortium in the neurosciences.
David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. He is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs. Until 2009, he was a professor at the University of Bristol heading their Psychopharmacology Unit. Since then he has been the Edmond J Safra chair in Neuropsychopharmacology at Imperial College London and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences there. Nutt was a member of the Committee on Safety of Medicines, and was President of the European College of Neuropsychopharmacology.
DrugScience or Drug Science (originally called the Independent Scientific Committee on Drugs (ISCD)) is a UK-based drugs advisory committee proposed and initially funded by hedge fund manager Toby Jackson. It is chaired by Professor David Nutt and was officially launched on 15 January 2010 with the help of the Centre for Crime and Justice Studies. The primary aim of the committee is to review and investigate the scientific evidence of drug harms without the political interference that could result from government affiliation.
The long-term effects of cannabis have been the subject of ongoing debate. Because cannabis is illegal in most countries, clinical research presents a challenge and there is limited evidence from which to draw conclusions. In 2017, the U.S. National Academies of Sciences, Engineering, and Medicine issued a report summarizing much of the published literature on health effects of cannabis, into categories regarded as conclusive, substantial, moderate, limited and of no or insufficient evidence to support an association with a particular outcome.
Substance-induced psychosis is a form of psychosis that is attributed to substance use. It is a psychosis that results from the effects of chemicals or drugs. Various psychoactive substances have been implicated in causing or worsening psychosis in users.
Glyn Lewis is a British professor of psychiatric epidemiology and the current head of the Division of Psychiatry at University College London
Sex differences in schizophrenia are widely reported. Men and women exhibit different rates of incidence and prevalence, age at onset, symptom expression, course of illness, and response to treatment. Reviews of the literature suggest that understanding the implications of sex differences on schizophrenia may help inform individualized treatment and positively affect outcomes.
Mary Cannon is an Irish psychiatrist, research scientist, public figure and former member of the Cannabis Risk Alliance. She has received the Royal Academy of Medicine in Ireland's "Doctors Award" for psychiatry, and is among the most highly cited scientists in the world. Cannon is known for her views on cannabis, being described as 'anti-cannabis'. She is best known in the field of psychiatry for her study of the risk factors for mental illness in young people.
Suzanne H. Gage is a British psychologist and epidemiologist who is interested in the nature of associations between lifestyle behaviours and mental health. She is a senior lecturer at the University of Liverpool and has a popular science podcast and accompanying book, Say Why to Drugs, which explores substance use.
Irene Mary Carmel Tracey is Vice-Chancellor of the University of Oxford and former Warden of Merton College, Oxford. She is also Professor of Anaesthetic Neuroscience in the Nuffield Department of Clinical Neurosciences and formerly Pro-Vice-Chancellor at the University of Oxford. She is a co-founder of the Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), now the Wellcome Centre for Integrative Neuroimaging. Her team’s research is focused on the neuroscience of pain, specifically pain perception and analgesia as well as how anaesthetics produce altered states of consciousness. Her team uses multidisciplinary approaches including neuroimaging.
Claudi Bockting is a Dutch clinical psychologist and Professor of Clinical Psychology in Psychiatry at the University of Amsterdams Faculty of Medicine, Amsterdam University Medical Centers. Her research program focuses on identifying etiological factors of common mental health disorders such as depression, anxiety disorders and substance abuse, and developing evidence-based psychotherapeutic interventions.
Ayana Jordan is an American addiction psychiatrist and immunopathologist. She researches treatments for substance use disorders in marginalized communities. She is the Barbara Wilson Associate Professor of Psychiatry at NYU Langone Health and was a professor at Yale School of Medicine. She served as an attending psychiatrist in the Yale University Department of Psychiatry. She was elected to the Board of Trustees of the American Psychiatric Association in 2018. She attended Hampton University and received her MD and PhD from the Albert Einstein College of Medicine.
References
- 1 2 3 4 5 6 7 Mitchell, Fiona (2017-02-01). "Anne Lingford-Hughes: to get into addiction, just say yes". The Lancet Psychiatry. 4 (2): 101. doi:10.1016/S2215-0366(16)30429-1. ISSN 2215-0366.
- ↑ "Home - Professor Anne Lingford-Hughes". www.imperial.ac.uk. Retrieved 2023-05-26.
- ↑ Breedvelt, Josefien J. F.; Rowe, Sarah; Bowden-Jones, Henrietta; Shridhar, Sunita; Lovett, Kate; Bockting, Claudi; Lingford-Hughes, Anne; Strathdee, Geraldine; Tracy, Derek K. (December 2018). "Unleashing talent in mental health sciences: gender equality at the top". Cambridge Core. Retrieved 2023-05-26.
- ↑ "Women, science, medicine, and psychiatry". www.rcpsych.ac.uk. Retrieved 2023-05-26.
- ↑ "The British Association for Psychopharmacology | News". www.bap.org.uk. Retrieved 2023-05-26.
| International | |
|---|---|
| National | |
| Academics | |
